CRISPR Epigenetic Therapy Shows Durable Remission in Rare Disease Clinical Trial

The Promise of Epigenetic Switches

BOSTON - Clinical genetics has entered a safer, more precise chapter as researchers published results from the first human clinical trial utilizing epigenetic CRISPR switches to permanently silence disease-driving genes.

Unlike traditional CRISPR-Cas9 tools that cut both strands of the DNA double helix (risking off-target insertions or chromosomal rearrangements), this therapy uses a catalytically inactive Cas enzyme coupled with a methylation writer.

The therapy chemically bookmarks the target PCSK9 gene in liver cells, turning off its expression permanently without altering the underlying genetic sequence.

All 18 trial patients experienced a 70 percent reduction in dangerous LDL cholesterol levels, maintaining optimal cardiovascular health two years after receiving a single lipid nanoparticle infusion.

Scientists believe this epigenetic methodology can be extended to treat autoimmune disorders, neurodegenerative conditions, and certain treatment-resistant cancers.